Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2014 Jul 20;32(21):2255-69. doi: 10.1200/JCO.2013.54.2258. Epub 2014 May 27.

2.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ; American Society of Clinical Oncology.

J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12. Review.

PMID:
20625130
3.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
4.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.

PMID:
17112447
5.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
6.

Optimal adjuvant endocrine therapy for early breast cancer.

Stuart-Harris R, Davis A.

Womens Health (Lond). 2010 May;6(3):383-98. doi: 10.2217/whe.10.25. Review.

PMID:
20426605
7.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
8.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2016 May 10;34(14):1689-701. doi: 10.1200/JCO.2015.65.9573. Epub 2016 Feb 16.

PMID:
26884586
9.
10.

Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.

Pan K, Chlebowski RT.

Clin Breast Cancer. 2014 Jun;14(3):147-53. doi: 10.1016/j.clbc.2013.12.010. Epub 2013 Dec 27. Review.

PMID:
24503025
11.

Breast cancer update.

Kuter I.

Oncologist. 2000;5(4):285-92.

12.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

13.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
14.
15.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87. Epub 2005 Jul 5.

PMID:
15998905
16.

Current controversies in extended adjuvant endocrine therapy for early breast cancer.

Snoj N, Paridaens R, Cufer T.

Curr Opin Oncol. 2008 Nov;20(6):627-33. doi: 10.1097/CCO.0b013e3283136770. Review.

PMID:
18841043
18.

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Mathew A, Davidson NE.

Breast. 2015 Nov;24 Suppl 2:S120-5. doi: 10.1016/j.breast.2015.07.027. Review.

PMID:
26255743
19.

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, OcaƱa A.

J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. Review.

PMID:
21743022
20.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456

Supplemental Content

Support Center